Biotech News

Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock

Prime Medicine (PRME)Prime MedicineFinancing

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of $125.0 million of

Related news

Prime Medicine

Prime Editing Prime Medicine develops genetic medicines using Prime Editing, a technology designed to make precise DNA changes without requiring double-strand breaks. Its programs target diseases that may be addressed by correcting pathogenic variants in vivo or ex vivo. PM577 PM577 is an in vivo Prime Editing candidate designed to...

Recent company news

Stock data

Close
3.84 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States